Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances.
To further evaluate the role exerted by endogenous opioids on LH secretion a naloxone challenge (0.08 mg/Kg b.w. i.v.) was performed in 23 healthy children at different stages of puberty, in 5 adolescents in different period of menstrual cycle, in 3 case of idiopathic precocious puberty (PP), in 7 cases of delayed puberty (DP), in 4 females affected by hypogonadotropic hypogonadism (HH) and in 6 patients affected by polycystic ovary disease (PCOD). Naloxone does not induce any significant change on LH plasma levels in prepubertal healthy children and in all the cases of PP and DP. Similarly there was no LH response in healthy adolescents neither in HH nor in PCOD, the response to naloxone appears only in preovulatory and luteal phases. These data indicate that the central opioid system regulating LH secretion in humans is active only at more advanced stages of puberty and it does not seem to play a role in the beginning of sexual maturation. Moreover gonadal steroids seem to play a fundamental modulatory role on opioid-controlled LH secretion.
Bernasconi
S
S
Petraglia
F
F
Iughetti
L
L
Facchinetti
F
F
Marcellini
C
C
Giovannelli
G
G
Genazzani
A R
AR
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000503:physiopathology; D007986:Luteinizing Hormone / Q000378:metabolism*; D008297:Male; D008597:Menstrual Cycle; D009270:Naloxone; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology; D011627:Puberty / Q000502:physiology*; D011628:Puberty, Delayed / Q000503:physiopathology; D011629:Puberty, Precocious / Q000503:physiopathology
D009270:Naloxone; D007986:Luteinizing Hormone